Person:
ÖZGÜVEN, SALİH

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ÖZGÜVEN

First Name

SALİH

Name

Filters

2022 - 202310
Reset filters

Settings

Has files: true × Subject: Klinik Tıp (MED) ×

Search Results

Now showing 1 - 10 of 10
  • Thumbnail Image
    PublicationOpen Access
    Role of baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment
    (2022-08-01) AKIN TELLİ, TUĞBA; ÖZGÜVEN, SALİH; FİLİZOĞLU, NUH; ÖZTÜRK, MEHMET SAADEDDİN; ARIKAN, RUKİYE; DEMİRCAN, NAZIM CAN; BAŞOĞLU TÜYLÜ, TUĞBA; ALSAN ÇETİN, İLKNUR; ÖNEŞ, TUNÇ; DANE, FAYSAL; YUMUK, PERRAN FULDEN; AKIN TELLİ T., ÖZGÜVEN S., Alan O., Filizoglu N., ÖZTÜRK M. S. , Sariyar N., Isik S., Arikan R., DEMİRCAN N. C. , BAŞOĞLU TÜYLÜ T., et al.
    Objective We aimed to evaluate whether baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters could be used as predictive biomarkers for survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line treatment. Materials and methods This retrospective study included 54 mCRPC patients, who underwent baseline Ga-68-PSMA PET/CT imaging within 1 month before starting first-line treatment. Pre-treatment prostate-specific antigen (PSA) levels and treatments were recorded. SUVmax, SUVmean, whole-body PSMA-derived tumor volume (wbPSMA-TV), and whole-body total lesion PSMA (wbTL-PSMA) were calculated for all patients. PSA response was defined as a decline of >= 50% from pre-treatment value at 12 weeks. Overall survival (OS) was measured from the start of the first-line treatment for mCRPC. Results Docetaxel and abiraterone/enzalutamide were administered to 32 and 22 patients in the first-line setting, respectively. wbPSMA-TV (rho = 0.582, p = 0.004) and wbTL-PSMA (rho = 0.564, p = 0.007) showed moderate positive correlations with PSA levels. Older age (p = 0.02), higher wbPSMA-TV (p = 0.007), higher PSA (p = 0.01), higher number of bone metastases (p = 0.02), and lack of PSA response (p = 0.03) were significantly associated with an increased risk of mortality. Multivariate analysis determined wbPSMA-TV (HR: 1.003, 95% CI 1.001-1.004, p = 0.001) and PSA response (HR: 2.241, 95% CI 1.189-4.222, p = 0.01) as independent predictors of OS. Conclusion The wbPSMA-TV may be a useful tool to reflect tumor burden and predict survival outcomes in patients with mCRPC.
  • Thumbnail Image
    PublicationOpen Access
    Corticomedullary Mixed Tumor of the Adrenal Gland with Apparent F-18-Fluorodeoxyglucose Activity But No 68GA-DOTATATE Uptake on Positron Emission Tomography/Computed Tomography
    (2022-07-01) ENGÜR, CEREN ÖZGE; APAYDIN, TUĞÇE; ÖNEŞ, TUNÇ; ÖZGÜVEN, SALİH; Engur C. O. , Apaydin T., ÖNEŞ T., Gozu H. I. , ÖZGÜVEN S.
    Corticomedullary mixed tumor (CMT) is a single adrenal tumor mass composed histologically by an admixture of adrenal cortical and medullary cells. It is a rare condition, with approximately 20 cases reported to date. To our knowledge, the positron emission tomography (PET) imaging findings of this mostly benign tumor have not been reported in the literature. We present a case of CMT who was evaluated with both F-18-fluorodeoxyglucose (F-18-FDG) and Ga-68-DOTATATE. The hypermetabolic tumor seen on F-18-FDG PET/computed tomography scan showed no abnormal uptake by Ga-68-DOTATATE.
  • Thumbnail Image
    PublicationOpen Access
    Recurrent Glomus Jugulare Tumor Invading the Cerebellum on 68Ga-DOTATATE PET/CT.
    (2022-05-01) ÖZGÜVEN, SALİH; Balaban Genc Z. C., Filizoglu N., Ozguven S.
    Glomus tumors are rare, slow-growing extra-adrenal paragangliomas of the head and neck. Treatment and prevention of neurological deficits become more difficult as these tumors aggressively grow in size and infiltrate adjacent anatomical structures. Because glomus tumors are paragangliomas of neuroendocrine origin, 68Ga-DOTATATE PET/CT can be used as imaging method in the diagnosis and follow-up. In this case, we presented a recurrent glomus jugulare tumor that invaded to the cerebellum on 68Ga-DOTATATE PET/CT imaging
  • Thumbnail Image
    PublicationOpen Access
    Ga-68-Tetraazacyclododecane Tetraacetic Acid-DPhe1-Tyr3-Octreotate Positron Emission Tomography/Computed Tomographic Findings of Large-Cell Neuroendocrine Carcinoma of the Lung in a Child
    (2022-10-01) FİLİZOĞLU, NUH; KESİM, SELİN; ÖZGÜVEN, SALİH; Filizoglu N., Kesim S., ÖZGÜVEN S.
    Primary lung cancers in children are rare, and most children are diagnosed incidentally while being investigated for another medical problem. The diagnosis of primary lung tumors in children is very difficult because many children are asymptomatic until the advanced stages of the disease and nonspecific imaging findings. Although the usage of 68Ga-tetraazacyclododecane tetraacetic acid-DPhe1-Tyr3-octreotate (68Ga-DOTATATE) positron emission tomography/computed tomography (PET/CT) in adult patients is well known, it is a relatively new imaging modality for the pediatric patient group. Herein, we presented a unique case of large-cell neuroendocrine carcinoma of the lung in a child on 68Ga-DOTATATE PET/CT.
  • Thumbnail Image
    PublicationOpen Access
    18 F-FDG PET/CT imaging of a Grade 3 lymphomatoid granulomatosis in an immunocompromised pediatric patient
    (2023-02-01) KESİM, SELİN; ÖZGÜVEN, SALİH; ÖNEŞ, TUNÇ; KESİM S., Şen F., ÖZGÜVEN S., ÖNEŞ T.
    Lymphomatoid granulomatosis is a rare extranodal Epstein-Barr virus-driven B-cell lymphoproliferative disease, involving predominantly lung, less often skin, kidney, and central nervous system. Here, we present a pediatric case with primary immunodeficiency, diagnosed with pathologically proven pulmonary grade-III lymphomatoid granulomatosis.18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging demonstrated18F-FDG avid pulmonary masses with central air-bronchograms and cavitations. Although the definitive diagnosis depends on biopsy,18F-FDG PET/CT serves as a complementary imaging tool to evaluate the extent of the disease and response to treatment.
  • Thumbnail Image
    PublicationOpen Access
    Predictive value of (18)F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy.
    (2022-05-01) UĞURLU, MUSTAFA ÜMİT; KÖSTEK, OSMAN; ÖZGÜVEN, SALİH; Başoğlu T., Özgüven S., Özkan H. Ş., Çınar M., Köstek O., Demircan N. C., Arıkan R., Telli T. A., Ercelep Ö., Kaya H., et al.
    Aim: We investigated the correlation between 18F-FDG PET/CT indices and pathological response in breast cancer treated with neoadjuvant chemotherapy (NACT) which was scored with Residual Cancer Burden (RCB) system after surgery. Our aim is to detect extensive residual cancer burden earlier by using PET/CT indices. Methods: Characteristics of patients were retrieved retrospectively. Baseline maximum Standart Uptake Value (SUVmax), Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG)indices and reduction rate (RR) between baseline and interim evaluation were calculated with FDG PET/CT scan. All patients were evaluated according to RCB scores after surgery. Pathological responses and PET/CT measurement results were analyzed with demographic and clinical parameters. Results: A total of 95 patients were included in the study. According to pathological responses, the distribution of RCB -0, -1, -2, -3 were 13 (13.7%), 11 (11.6%), 30 (31.6%), 41 (43.2%), respectively. Diseasefree survival was significantly lower in the RCB3 group compared to the pathological responder group (p = 0.01). According to multivariate analysis, RR of SUVmax was determined as an independent variable predicting extensive residual cancer burden with an optimal cut-off value of 86% (p < 0.05). Conclusions: We determined RR of SUVmax as an independent factor for predicting extensive residual tumor burden. We believe that RR of SUVmax is sufficient to predict pathological response in daily practice. In addition, MTV and TLG measurements do not contribute additionally to SUVmax alone and can cause unnecessary labor loss.
  • Thumbnail Image
    PublicationOpen Access
    Incidental Ga-68 DOTATATE uptake in an aggressive vertebral hemangioma.
    (2022-02-19) ÖZGÜVEN, SALİH; Kesim S., Oksuzoglu K., Ozguven S.
  • Thumbnail Image
    PublicationOpen Access
    Şiddetli kaudal regresyon sendromu olan pediatrik bir hastada tek foton emisyonlu bilgisayarlı tomografi/bilgisayarlı tomografi ile hibrid renal kortikal görüntüleme
    (2022-02-01) KESİM, SELİN; TUROĞLU, HALİL TURGUT; ÖZGÜVEN, SALİH; ERDİL, TANJU YUSUF; ÖNEŞ, TUNÇ; KESİM S., TUROĞLU H. T., ÖZGÜVEN S., ÖNEŞ T., ERDİL T. Y.
    © 2022 by Turkish Society of Nuclear Medicine Molecular Imaging and Radionuclide Therapy published by Galenos Yayınevi.Caudal regression syndrome (CRS) or sacral agenesis is a rarely seen malformation with a varying degree of structural abnormalities, including multiorgan system dysfunctions, reported with higher incidence among children of mothers with diabetes, as in this case. Spinal anomalies can range from coccyx hemiagenesis to the total absence of lower lumbar vertebrae and sacrum in most severe cases. Herein, we have presented a 9-year-old patient with CRS who had renal failure. Technetium-99m dimercaptosuccinic acid renal scintigraphy revealed bilaterally non-functioning kidneys with no renal cortical uptake. Renal anomalies in CRS with vertebral, anorectal, cardiac, trachea-esophageal, renal, and limb anomalies association include one-sided renal agenesis, multicystic dysplastic kidneys, and ureter duplications.
  • Thumbnail Image
    PublicationOpen Access
    A rare case of pituitary carcinoma with bone metastases: Ga-68-DOTATATE PET/CT findings
    (2022-03-01) FİLİZOĞLU, NUH; ÖZGÜVEN, SALİH; Filizoglu N., ÖZGÜVEN S.
    Pituitary carcinomas are extremely rare and aggressive tumors that comprise only 0.2% of all pituitary tumors. Because of its rarity, pituitary carcinomas are difficult to diagnose. Conventional imaging methods are inadequate to detect metastatic lesions. Pituitary carcinomas are neuroendocrine tumors and express somatostatin receptors; therefore, Ga-68-DOTATATE PET/CT may be used in the staging of these rare tumors. Herein, we present an exceptional case of pituitary carcinoma with sclerotic skeletal metastases showing Ga-68-DOTATATE uptake.
  • Thumbnail Image
    PublicationOpen Access
    Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib
    (2022-08-01) DEMİRCAN, NAZIM CAN; ENGÜR, CEREN ÖZGE; AKIN TELLİ, TUĞBA; BAŞOĞLU TÜYLÜ, TUĞBA; ARIKAN, RUKİYE; ÖZGÜVEN, SALİH; DANE, FAYSAL; KAYA, HANDAN; ÖNEŞ, TUNÇ; YUMUK, PERRAN FULDEN; DEMİRCAN N. C. , ENGÜR C. Ö. , AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., Arikan R., Yasar A., Celebi A., Alan O., Isik S., ÖZGÜVEN S., et al.
    OBJECTIVE We investigated the relationship of baseline sarcopenia with toxicities, treatment response, and survival in patients who had non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation and received erlotinib.METHODS Computed tomography images from PET/CT scans before erlotinib treatment were retrospectively assessed. Skeletal muscle index, calculated as skeletal muscle area at third lumbar vertebra level/square of height, was used to define sarcopenia with < 52.4 cm2/m2 for males and < 38.5 cm2/m2 for females. Cox hazard models were conducted to determine predictors of survival.RESULTS The study included 30 patients, and 11 (36.7%) were sarcopenic. All-grade and Grade 3 toxicities were more frequent in sarcopenic group, although it was statistically insignificant (81.8% vs. 63.2%, p=0.282 for all-grade, and 18.2% vs. 10.5%, p=0.552 for grade 3). Response rates were 63.6% in sarcopenic and 68.4% in non-sarcopenic patients (p=0.789). Median progression-free survival was 7.9 and 9.2 months in sarcopenic and non-sarcopenic cases, respectively (p=0.561). However, median overall survival (OS) of sarcopenic patients was significantly shorter than non-sarcopenic ones (11.8 vs. 30.2 months, p=0.023), and sarcopenia predicted OS independently in multivariate analysis (Hazard ratio=2.63, p=0.029).CONCLUSION Early recognition, treatment, and prevention of sarcopenia may improve long-term survival in EGFRmutant NSCLC patients treated with first-line erlotinib.